- Stocks
- Healthcare
- NASDAQ: DXCM

Price (delayed)

$105.915

Market cap

$40.91B

P/E Ratio

179.52

Dividend/share

N/A

EPS

$0.59

Enterprise value

$42.28B

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. It operates internationally with headquarters in San Diego, California. Dexcom was founded in

Dexcom's revenue has increased by 20% YoY and by 4.5% from the previous quarter

DXCM's gross profit is up by 13% year-on-year and by 2.7% since the previous quarter

The EPS has shrunk by 61% YoY but it rose by 5% QoQ

Dexcom's net income has plunged by 60% YoY but it has increased by 6% from the previous quarter

The quick ratio has declined by 26% year-on-year and by 21% since the previous quarter

The company's equity fell by 19% QoQ and by 15% YoY

What are the main financial stats of DXCM

Market
Valuations
Earnings

Shares outstanding

386.26M

Market cap

$40.91B

Enterprise value

$42.28B

Price to earnings (P/E)

179.52

Price to book (P/B)

22.79

Price to sales (P/S)

14.78

EV/EBIT

150.75

EV/EBITDA

97.83

EV/Sales

15.14

Revenue

$2.79B

EBIT

$280.5M

EBITDA

$432.2M

Free cash flow

$261.3M

Per share
Balance sheet
Liquidity

EPS

$0.59

Free cash flow per share

$0.67

Book value per share

$4.65

Revenue per share

$7.16

TBVPS

$12.44

Total assets

$4.9B

Total liabilities

$3.07B

Debt

$2.07B

Equity

$1.82B

Working capital

$2.5B

Debt to equity

1.14

Current ratio

3.77

Quick ratio

3.26

Net debt/EBITDA

3.18

Margins
Efficiency
Dividend

EBITDA margin

15.5%

Gross margin

65%

Net margin

8.2%

Operating margin

9.5%

Return on assets

4.6%

Return on equity

11.1%

Return on invested capital

5.1%

Return on capital employed

7%

Return on sales

10%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Dexcom stock price performed over time

Intraday

-0.75%

1 week

-0.46%

1 month

-6.47%

1 year

2.48%

YTD

-6.47%

QTD

-6.47%

How have Dexcom's revenue and profit performed over time

Revenue

$2.79B

Gross profit

$1.81B

Operating income

$266.4M

Net income

$230M

Gross margin

65%

Net margin

8.2%

The net margin has plunged by 67% YoY

Dexcom's net income has plunged by 60% YoY but it has increased by 6% from the previous quarter

The operating margin has declined by 40% year-on-year but it has increased by 7% since the previous quarter

DXCM's operating income is down by 28% year-on-year but it is up by 12% since the previous quarter

What is Dexcom's growth rate over time

What is Dexcom stock price valuation

P/E

179.52

P/B

22.79

P/S

14.78

EV/EBIT

150.75

EV/EBITDA

97.83

EV/Sales

15.14

The EPS has shrunk by 61% YoY but it rose by 5% QoQ

The stock's price to earnings (P/E) is 10% less than its last 4 quarters average of 202.1

The company's equity fell by 19% QoQ and by 15% YoY

DXCM's P/B is 17% above its last 4 quarters average of 19.6 and 12% above its 5-year quarterly average of 20.5

Dexcom's revenue has increased by 20% YoY and by 4.5% from the previous quarter

The stock's price to sales (P/S) is 5% less than its last 4 quarters average of 15.7

How efficient is Dexcom business performance

Dexcom's ROA has plunged by 64% YoY but it has increased by 7% from the previous quarter

The ROE has dropped by 62% year-on-year but it is up by 11% since the previous quarter

The ROS fell by 38% YoY but it rose by 6% QoQ

DXCM's return on invested capital is down by 37% year-on-year but it is up by 6% since the previous quarter

What is DXCM's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for DXCM.

How did Dexcom financials performed over time

The company's total assets is 59% higher than its total liabilities

The quick ratio has declined by 26% year-on-year and by 21% since the previous quarter

Dexcom's current ratio has decreased by 24% YoY and by 20% QoQ

The debt is 14% more than the equity

DXCM's debt to equity is up by 34% YoY and by 24% QoQ

The company's equity fell by 19% QoQ and by 15% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.